Alkermes plc. ($ALKS)
Filing Information
| Accession Number | 0001520262-26-000110 |
|---|---|
| Form Type | 4 |
| Filing Date | Aug 3, 2026 |
| Document | View SEC Filing |
Transactions
5
Total Shares
19,000
Total Value
$559,624.00
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EVP R&D, Chief Medical Officer | Ordinary Shares | โ | Aug 3, 2026 | Exercise/Conversion | 104 | $19.34 | $2,011.36 | 73,493 | Direct | โ | View Details | |
EVP R&D, Chief Medical Officer | Ordinary Shares | โ | Aug 3, 2026 | Exercise/Conversion | 4,896 | $24.59 | $120,392.64 | 78,389 | Direct | โ | View Details | |
EVP R&D, Chief Medical Officer | Ordinary Shares | โ | Aug 3, 2026 | Sale | 9,000 | $48.58 | $437,220.00 | 69,389 | Direct | โ | View Details | |
EVP R&D, Chief Medical Officer | Employee Stock Option (Right to Buy) | Derivative | Aug 3, 2026 | Exercise/Conversion | 104 | $0.00 | $0.00 | 1,252 | Direct | โ | View Details | |
EVP R&D, Chief Medical Officer | Employee Stock Option (Right to Buy) | Derivative | Aug 3, 2026 | Exercise/Conversion | 4,896 | $0.00 | $0.00 | 66,276 | Direct | โ | View Details |